Seroprevalence of Monkeypox Infection Among People Living With HIV and PrEP Users

NCT ID: NCT05922735

Last Updated: 2023-06-28

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 5000 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2023-09-01
• Study Completion Date: 2025-02-01

Brief Summary

This is a cohort, non-health product, non-interventional biomedical research, multi-centric, to determine the seroprevalence of mpox infection in the population of people living with HIV and in PrEP users in Ile-de-France and in the province.

Detailed Description

The target population is the population of people living with HIV (PLHIV) (n=18,500) and PrEP users (n=4930) followed up in Parisian infectious and tropical diseases departments (SMIT) of the Pitié-Salpêtrière, Tenon, Saint-Antoine, Bichat, Saint-Louis, Necker hospitals, the University Department of Infectious and Traveller Diseases of Hôpital Dron (Tourcoing), the 190 health center, and the Maison de santé du Chemin vert (Paris).

The principal objective is to determine the seroprevalence of Monkeypox infection in the population of PLHIV and PrEP users followed in the infectious and tropical disease departments in 9 centers.

In addition to the primary objective, there exist the following secondary objectives:

• To assess the level of anti-Mpox antibodies in PLHIV and PrEP users
• To assess the level of anti-Mpox antibodies in PLHIV and PrEP users with a previous confirmed diagnosis of Mpox or if they have been recently vaccinated
• Assess antibody levels in PLHIV in relation to CD4 cell count and HIV viral load
• Study antibody kinetics and persistence over time (D0 (between November 1, 2021 and April 30, 2022), M6, M12)
• Study the Mpox seroconversion rate over time
• Determine the neutralizing activity of anti-Mpox antibodies in individuals with positive anti-Mpox ELISA serology.
• Describe the natural history of the disease, the different forms of the disease, their clinical characterization
• Describe sexual behavior and the impact of this health crisis on different aspects of their lives using a self-administered questionnaire
• To determine the prevalence of asymptomatic infections
• Proportion of participants with positive Mpox serology without PCR confirmed diagnosis
• History of childhood or recent smallpox vaccination

During the patient's follow-up consultation, after information and in the absence of an expression of no objection, inclusion will consist of recovering a blood sample taken between November 2021 and April 2022 during the HIV infection assessment or PrEP follow-up (no additional sample) and possibly the blood sample taken at M6 and/or M12 if this follow-up consultation has already taken place.

An online self-questionnaire will also be proposed to the patient (male only). It will be constructed from questions already validated in other surveys (Rapport au Sexe, Prévenir, Parcours).

A check on the appearance or persistence of antibodies will be carried out at M6 +/- 8 weeks and/or M12 +/- 8 weeks on tube bottoms of samples always taken as part of the HIV infection assessment or PrEP follow-up.

Conditions

Monkey Pox; HIV Infections

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: RETROSPECTIVE

Study Groups

Population living with HIV and PrEP users

Population of people living with HIV and PrEP users followed in the infectious disease departments in Ile de France and in the province.

Questionnaire

Intervention Type: BEHAVIORAL

Serology from remaining blood sample Self-questionnaire about sexual behavior during the epidemy mpox

Interventions

Questionnaire

Serology from remaining blood sample Self-questionnaire about sexual behavior during the epidemy mpox

Intervention Type: BEHAVIORAL

Eligibility Criteria

Inclusion Criteria

• Age ≥ 18 years
• People Living with HIV or PrEP users with a blood test within 6 months before the start of the epidemic (i.e. between 1/11/2021 and 30/04/2022, D0) and with a blood test scheduled at M6 and/or at M12 of this collection depending on the care, in the centers participating in the study
• Having been informed about the study and not having expressed his opposition
• Affiliated to a social security system or entitled person, AME beneficiary

Exclusion Criteria

• Refusal of participation by the patient
• Under legal protection (guardianship/guardianship)
• Not able to understand the information and/or express opposition and/or not speaking French

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

INSERM UMR S 1136

OTHER

Sponsor Role: collaborator

Institut de Recherche en Santé Publique, France

OTHER

Sponsor Role: collaborator

Institut Pasteur

INDUSTRY

Sponsor Role: collaborator

ANRS, Emerging Infectious Diseases

OTHER_GOV

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Valérie POURCHER, Pr

Role: PRINCIPAL_INVESTIGATOR

Assistance Publique - Hôpitaux de Paris

Central Contacts

Simon AMADOR PAZ

Role: CONTACT

simon.amador-paz@anrs.fr

01 53 94 80 78

Alexia PAUCARD

Role: CONTACT

alexia.paucard@iplesp.upmc.fr

01 42 16 42 55

Other Identifiers

ANRS 0297s MonVIP

Identifier Type: -

Identifier Source: org_study_id